Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

27.30 +18.43 (+207.78%)
Streaming Delayed Price Updated: 12:46 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Mersana Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout ↗
Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio. 
Via Benzinga
News headline image
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results ↗
 
Via Benzinga
News headline image
An Overview of Mersana Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Earnings Preview For Mersana Therapeutics ↗
 
Via Benzinga
News headline image
Mersana Catapults 200% On Day One Bio's Surprise Buyout ↗
Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it. 
Via Investor's Business Daily
News headline image
MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal ↗
The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday. 
Via Stocktwits
News headline image
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts ↗
 
Via Benzinga
News headline image
Mersana Misses Fiscal Q2 Revenue Target ↗
Via The Motley Fool
News headline image
A Look at Mersana Therapeutics's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Thursday's session: gap up and gap down stocks ↗
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Earnings Scheduled For August 13, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Top movers in Thursday's after hours session ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
News headline image
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? ↗
Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast cancer. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
MRSN Stock Earnings: Mersana Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗
MRSN stock results show that Mersana Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
MRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
MRSN stock results show that Mersana Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.